The associations between clinicopathological features and the expression of PTEN, AKT, ERK, and P65 markers provide a basis for further investigations into the precise roles of these signaling pathways in various stages of CRC development, aiding in the understanding of potential therapeutic targets and prognostic markers. This evidence concerns the gene AKT1 and colorectal carcinoma.